Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep and Danisco Announce the first Betaine Industrial Production Process from Bioethanol Side-stream

Published: Thursday, December 16, 2010
Last Updated: Thursday, December 16, 2010
Bookmark and Share
Novasep Process and Danisco announces the scale-up of an innovative process for the production of natural betaine. The plant will be the first to exploit a new extraction process using vinasse, a byproduct of sugar-beet-derived bioethanol.

This process will enable Danisco to substantially increase the availability of natural betaine, which is globally used as a technical animal feed ingredient and currently in short supply.
 
Danisco pioneered the research and application of natural betaine in animal nutrition in the early 1990s and has clearly demonstrated superior value compared to synthetic alternatives. Unlike synthetic betaine, natural betaine acts as an osmolyte, improving intestinal health and reducing the negative impact of heat-stress on animal production. Currently, market demand for natural betaine outweighs production. The betaine from the new plant will be sold by Danisco as Betafin(TM).
 
As well as increasing the availability of betaine, the new process will allow the betaine-extracted bioethanol vinasses (residues) to be further recycled and sold as crop fertilizer. Until now, it was possible to extract natural betaine only from sugar-beet molasses, a side stream of sugar production. The new process will be increasingly valuable as the increase of the bioethanol production using beets will generate more and more vinasses.
 
Novasep Process is responsible for the engineering of the new plant and will provide the complete process line which combines Danisco’s proprietary chromatographic technology, known as NS2P, with membrane and evaporation steps. This project is the latest development of the FAST alliance between Novasep and Danisco in the field of betaine extraction and purification, which has already given birth to several betaine production plants.
 
“I am delighted about this new milestone in our longstanding relationship with Danisco,” said Antoine Baule, president of Novasep Process, the bioprocess division of Novasep. “By playing a key role in this project, Novasep has again demonstrated its leadership in the development or scale-up of innovative processes in the industrial biotech industry, and its ability to collaborate with key customers and engineering partners in the long term through win-win partnerships.”
 
Juhani Kuusisto, director of operations at Danisco in charge of betaine sourcing added: “I am very happy about our cooperation with Novasep Process. This new project demonstrates Danisco’s ability to adjust to new market developments and to adapt its NS2P process to new feedstock. This process will substantially increase natural betaine availability on the market place.”
 
Danisco and Novasep will provide technological support for the betaine production plant with De Smet Engineering and Contractors, being in charge of building construction, erection services and auxiliaries supply of the new development. Tereos, a world player in sugar, starch and bioethanol production, will supply the vinasses and operate the plant at its facility in Origny, France.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Synthesis and Kilo Lab Extensions to US facility
Company builds a new synthesis laboratory and a kilo lab for US facility.
Tuesday, February 09, 2016
Novasep Adds Synthesis and Kilo Lab Extensions to US Facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers.
Saturday, February 06, 2016
Novasep, Advanced Biotherapeutics Team Up
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy.
Wednesday, January 13, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Reports Full Year 2013 Results
Results show strong growth and beating guidance.
Friday, March 28, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!